Home Technology Pipeline Our Team Contact Us
Developing Next Generation for the treatment of

Board of Directors

Geoffrey W. Smith has been an active founder, manager, and investor in healthcare and technology companies since 1995. Geoff currently serves on the Board of Directors of Azevan Pharmaceuticals, Biomerix Corporation, Crosstrees Medical, Inc., and Vivios Pharmaceuticals and is a Board Observer for ARYx Therapeutics and Cara Therapeutics. Geoff also serves on the Board of Trustees for Continuum Health Partners, a nonprofit hospital system in New York City that comprises five historically distinguished hospitals: Beth Israel Medical Center, St. Luke’s Hospital, Roosevelt Hospital, Long Island College Hospital, and The New York Eye and Ear Infirmary. Earlier in his career, Geoff was a corporate attorney in New York City. Prior to receiving his law degree, he served as a Research Associate at Harvard Business School. Geoff received a B.A. with honors from Williams College and a J.D. from the University of Pennsylvania Law School.


Dr. Michael Pavia joined Oxford Bioscience Partners as an Entrepreneur-in-Residence in 2002. Prior to joining Oxford, Dr. Pavia was Chief Technology Officer at Millennium Pharmaceuticals, where his major focus was to improve the productivity of the drug discovery and development process through the appropriate use of new technologies. Dr. Pavia has 20 years experience in pharmaceutical research and discovery. He was formerly Vice President-Cambridge Research at Sphinx Pharmaceuticals, a division of Eli Lilly & Co., focusing on the development of combinatorial chemistry technologies. Prior to Sphinx, Dr. Pavia held senior scientific positions in the Department of Chemistry at the Parke-Davis Pharmaceutical Research Division of Warner-Lambert. He holds a B.S. in Chemistry from Lehigh University and a Ph.D. in Organic Chemistry from the University of Pennsylvania.


Dr. Paul Maddon is a Vice-Chairman of the Board of Directors of Progenics, where he is the founder and had served in various capacities. Dr. Maddon serves as chair of the advisory committee of The Rockefeller University's Science Outreach Program and is a member of Rockefeller's University Council and the Bridges to Better Medicine Committee. He serves as a trustee of Columbia University and is a member of the advisory committee of Columbia's Science Honors Program. At Columbia, Dr. Maddon was graduated summa cum laude with a B.A. in biochemistry and was elected to Phi Beta Kappa. He received an M.D. from Columbia's College of Physicians and Surgeons and a Ph.D. in biochemistry and molecular biophysics from its Graduate School of Arts and Sciences. A molecular virologist and immunologist by training, he has made seminal contributions to understanding viral entry and infection.


Carter Meyer has been the chief executive officer of Scientific Health Development (SHD) since its formation in February 2006, and is a general partner of its newest fund. Located in Dallas, Texas, SHD is an investment fund focused on earlier-stage life science companies. Mr. Meyer is a director of all SHD portfolio companies. Prior to joining SHD, Mr. Meyer was an attorney in private practice for more than 12 years, most recently with the Dallas office of Vinson & Elkins L.L.P. Mr. Meyer has a B.B.A. in finance from Texas Christian University and a J.D. from St. Mary’s University School of Law.


Dr. Neal G. Simon, CEO, has headed Azevan Pharmaceuticals since 1999. Dr. Simon is the former Chair of Biological Sciences at Lehigh University. He has over 25 years research experience in behavioral neurobiology. His research in drug development, hormone-neurotransmitter interactions, and behavioral regulation has been supported by the National Institutes of Health, the National Science Foundation, the Ben Franklin Northeast Tier Technology Partnership, the Life Sciences Greenhouse of Central PA, and the H.F Guggenheim Foundation, and private corporations. He serves on foundation and scientific advisory boards and consults for biotechnology companies. Dr. Simon received a B.A. with honors from the State University of New York at Binghamton, the M.S. and Ph.D. from Rutgers University, and was a National Research Service Postdoctoral Fellow at the State University of New York at Stony Brook. In 1996, he served as a Distinguished Research Professor at Université Louis Pasteur in Strasbourg, France.